Sanofi: Mastocytosis, Systemic trials
The registry lists 10 Mastocytosis, Systemic studies with Sanofi as lead sponsor. 4 are open to participants now and 1 have results posted.
Phase 1 2Phase 2 3Phase 3 1Phase 4 1No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)RecruitingNCT07264959
- A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in GermanyRecruitingNCT07255638
- Avapritinib Rollover StudyRecruitingNCT06748001Phase 4
- (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic MastocytosisRecruitingNCT04910685Phase 2/3
- (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic MastocytosisCompletedNCT03580655Phase 2Results posted
- Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic MalignanciesTerminatedNCT05609942Phase 1
- Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSMCompletedNCT04695431
- (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic MastocytosisActive, not recruitingNCT03731260Phase 2
- Mast Cell Connect: A Registry for Patients With MastocytosisCompletedNCT02620254
- (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid MalignanciesCompletedNCT02561988Phase 1